glp-1 agonist or antagonist Receptor Agonists as Treatments for Type 2 Diabetes GLP1 Receptor Agonists—Effects beyond Obesity

[DOI] [PubMed] [Google Scholar] 7.Kim S.Y., Oh M.R., Kim M.G., Chae H.J., Chae S.W

Consequently, several therapeutic approaches have aimed to antagonize GCG activity in the management of T2DM

GLP-1 agonists: act on the metabolism upstream by extrahepatic path The emergence of glucagon-like peptide-1 (GLP-1) agonists as a treatment option for diabetes and obesity has prompted their examination in patients with MASH 5

Similarly, as a result of the positive findings from the recent DAPA-CKD trial [90], dapagliflozin is now indicated for the treatment of CKD, and can be initiated if eGFR 25 ml/min/1.73 m 2

For biosynthesis, it seems the only strategy to prolong the half-life is a ligand fused with a terminal albumin or Fc domain, whose critical points are length and location